nipocalimab

Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

nipocalimab

Medical Information

+ Save link

Nipocalimab - Comparison to Other FcRn Blockers in Patients with Generalized Myasthenia Gravis

Last Updated: 12/03/2024

SUMMARY

Nipocalimab, a fully human, aglycosylated, effectorless immunoglobulin G1 (IgG1) anti- neonatal fragment crystallizable receptor (FcRn) monoclonal antibody, is an
investigational agent being studied for the treatment of adult and pediatric patients with generalized myasthenia gravis (gMG).¹^-³
There are no head-to-head, randomized, controlled clinical trials comparing the safety and efficacy of nipocalimab to other FcRn blockers in patients with gMG.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 11 November 2024.

References

Show

1	Ramachandren S, Sanga P, Burcklen M, et al. Vivacity MG phase 3 study: clinical trial of nipocalimab administered to adults with generalized myasthenia gravis. Oral Presentation presented at: 8th European Academy of Neurology Congress; June 25-28, 2022; Vienna, Austria.
2	Antozzi C, Guptill J, Bril V, et al. Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis. Neurology. 2024;102(2):e207937.
3	Ramchandren S, Black S, Sun H, et al. Vibrance-mg: clinical trial of nipocalimab in pediatric myasthenia gravis. Poster presented at: 8th European Academy of Neurology Congress; June 25-28, 2022; Vienna, Austria.